BRPI1016185A2 - processo para o tratamento de distúrbios associados à atividade da proteína quinase ck2 - Google Patents
processo para o tratamento de distúrbios associados à atividade da proteína quinase ck2Info
- Publication number
- BRPI1016185A2 BRPI1016185A2 BRPI1016185A BRPI1016185A BRPI1016185A2 BR PI1016185 A2 BRPI1016185 A2 BR PI1016185A2 BR PI1016185 A BRPI1016185 A BR PI1016185A BR PI1016185 A BRPI1016185 A BR PI1016185A BR PI1016185 A2 BRPI1016185 A2 BR PI1016185A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein kinase
- kinase activity
- disorders associated
- treating disorders
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17046809P | 2009-04-17 | 2009-04-17 | |
| US24016509P | 2009-09-04 | 2009-09-04 | |
| US24222709P | 2009-09-14 | 2009-09-14 | |
| US29766910P | 2010-01-22 | 2010-01-22 | |
| PCT/US2010/031520 WO2010121225A2 (en) | 2009-04-17 | 2010-04-16 | Method of treating disorders associated with protein kinase ck2 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016185A2 true BRPI1016185A2 (pt) | 2016-04-19 |
Family
ID=42981447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016185A BRPI1016185A2 (pt) | 2009-04-17 | 2010-04-16 | processo para o tratamento de distúrbios associados à atividade da proteína quinase ck2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100267753A1 (pt) |
| EP (1) | EP2419101A2 (pt) |
| JP (1) | JP2012524076A (pt) |
| KR (1) | KR20120044281A (pt) |
| CN (1) | CN102481289A (pt) |
| AU (1) | AU2010236162A1 (pt) |
| BR (1) | BRPI1016185A2 (pt) |
| CA (1) | CA2758974A1 (pt) |
| IL (1) | IL215712A0 (pt) |
| MX (1) | MX2011010918A (pt) |
| RU (1) | RU2011146544A (pt) |
| SG (1) | SG175210A1 (pt) |
| WO (1) | WO2010121225A2 (pt) |
| ZA (1) | ZA201107773B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2767273A1 (en) * | 2013-02-15 | 2014-08-20 | Universitätsklinikum Erlangen | Death-associated protein kinases, inhibitors and activators thereof for use in pharmaceutical compositions and in predictive medicine |
| CN105457029A (zh) * | 2014-09-29 | 2016-04-06 | 中国科学院上海巴斯德研究所 | 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用 |
| WO2017198847A1 (en) * | 2016-05-20 | 2017-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption |
| US20200009134A1 (en) * | 2017-03-03 | 2020-01-09 | Gritscience Biopharmaceuticals Co., Ltd. | Method and Compound for Modifying Circadian Clock |
| CA3067871A1 (en) * | 2017-07-31 | 2019-02-07 | The Regents Of The University Of California | Anti-cancer/anti-fibrosis compounds |
| CN111936484A (zh) | 2017-12-22 | 2020-11-13 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物 |
| TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| CN113444084A (zh) * | 2020-03-26 | 2021-09-28 | 东南大学 | 一类抗肿瘤化合物及其制备与用途 |
| CN112274642A (zh) * | 2020-10-15 | 2021-01-29 | 北京大学人民医院 | Ck2抑制剂在制备类风湿关节炎治疗药物中的应用 |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| CN114957252B (zh) * | 2022-07-14 | 2023-09-05 | 苏州施安鼎泰生物医药技术有限公司 | 一种化合物及其制备方法以及药物组合物和在制备eed抑制剂中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2724B1 (en) * | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| EP2061765B1 (en) * | 2006-09-01 | 2014-10-22 | Senhwa Biosciences, Inc. | Serine-threonine protein kinase and PARP modulators |
| CN102036561A (zh) * | 2008-02-29 | 2011-04-27 | 赛林药物股份有限公司 | 蛋白激酶调节剂 |
-
2010
- 2010-04-16 KR KR1020117027302A patent/KR20120044281A/ko not_active Application Discontinuation
- 2010-04-16 US US12/762,038 patent/US20100267753A1/en not_active Abandoned
- 2010-04-16 CA CA2758974A patent/CA2758974A1/en not_active Abandoned
- 2010-04-16 RU RU2011146544/04A patent/RU2011146544A/ru not_active Application Discontinuation
- 2010-04-16 BR BRPI1016185A patent/BRPI1016185A2/pt not_active Application Discontinuation
- 2010-04-16 CN CN2010800268072A patent/CN102481289A/zh active Pending
- 2010-04-16 EP EP10765314A patent/EP2419101A2/en not_active Withdrawn
- 2010-04-16 WO PCT/US2010/031520 patent/WO2010121225A2/en active Application Filing
- 2010-04-16 SG SG2011074747A patent/SG175210A1/en unknown
- 2010-04-16 JP JP2012505989A patent/JP2012524076A/ja active Pending
- 2010-04-16 MX MX2011010918A patent/MX2011010918A/es not_active Application Discontinuation
- 2010-04-16 AU AU2010236162A patent/AU2010236162A1/en not_active Abandoned
-
2011
- 2011-10-11 IL IL215712A patent/IL215712A0/en unknown
- 2011-10-24 ZA ZA2011/07773A patent/ZA201107773B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL215712A0 (en) | 2012-01-31 |
| WO2010121225A3 (en) | 2011-01-06 |
| EP2419101A2 (en) | 2012-02-22 |
| CN102481289A (zh) | 2012-05-30 |
| ZA201107773B (en) | 2012-07-25 |
| JP2012524076A (ja) | 2012-10-11 |
| US20100267753A1 (en) | 2010-10-21 |
| SG175210A1 (en) | 2011-11-28 |
| AU2010236162A1 (en) | 2011-11-03 |
| CA2758974A1 (en) | 2010-10-21 |
| KR20120044281A (ko) | 2012-05-07 |
| RU2011146544A (ru) | 2013-05-27 |
| WO2010121225A2 (en) | 2010-10-21 |
| MX2011010918A (es) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016185A2 (pt) | processo para o tratamento de distúrbios associados à atividade da proteína quinase ck2 | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| BRPI1010759A2 (pt) | processo para produção de proteína | |
| BRPI0906746A2 (pt) | Aparelho para tratamento de doença de refluxo gastresofágico | |
| BRPI1010766A2 (pt) | processo para rebaudiosídeo d | |
| BR112013009486A2 (pt) | processo para preparação de formas de dosagem gastrirretentivas multiparticuladas | |
| BRPI1006979A2 (pt) | métodos para tratar infartos agudos do miocárdio e distúrbios associados | |
| BRPI1010868A2 (pt) | terapia gênica para distúrbios neurodegenerativos | |
| BR112013007678A2 (pt) | método para tratamento de doenças alérgicas | |
| BRPI1014606A2 (pt) | Maltotriosil transferase, processo para produção e uso da mesma | |
| BRPI0610693A2 (pt) | métodos para tratamento de transtornos relacionados à ansiedade | |
| BRPI1007367A2 (pt) | processo para fabricação e resolução de ácido 2-acilamino-3-difenilpropanoico. | |
| BRPI0819688A2 (pt) | Processo para tratamento de fratura óssea com anticorpos anti-esclerostina. | |
| BRPI0908715A2 (pt) | métodos para tratamento da psoríase | |
| BR112013029507A2 (pt) | método para tratar uma doença ou um distúrbio | |
| BRPI0910454A2 (pt) | processo para produção de uma proteína policlonal | |
| BRPI0816911A2 (pt) | Processo para preparação de 4-aminobut-2-enolidas | |
| BR112013030381A2 (pt) | reagentes e métodos para tratar doença dental | |
| BRPI0920334A2 (pt) | métodos para o tratamento de distúrbios pulmonares com formulações de amicacina lipossomal. | |
| BRPI0914788A2 (pt) | Processo para a produção de um produto intermediário de etexilato de dabigatran | |
| BR112012000098A2 (pt) | Processo para identificação de compostos para tratar câncer | |
| BR112015007975A2 (pt) | processo para preparar continuamente tetrapolímeros, e tetrapolímero | |
| BR112013031117A2 (pt) | scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. | |
| BRPI0813960A2 (pt) | Processo para produção de biarilas | |
| BRPI1008987A2 (pt) | processo para preparar 3,3,3-trifluoropropeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |